Form 4: Boundless Bio Director James Christensen Granted 16,000 Stock Options

Boundless Bio, Inc. Director James Christensen was granted 16,000 stock options with an exercise price of $1.03, vesting over 12 months.

Summary

• James Christensen, a Director of Boundless Bio, Inc. (BOLD), acquired 16,000 stock options.
• The stock options have an exercise price of $1.03 per share.
• The transaction date for the grant was June 23, 2025.
• The options are set to vest in substantially equal monthly installments over the 12 months following June 23, 2025.
• Vesting may occur earlier if the next annual meeting of the issuer's stockholders takes place prior to June 23, 2026, at which point any remaining unvested portion will vest.
• The vesting is contingent upon Mr. Christensen's continued service on the issuer's board of directors through the vesting date.
• The stock options are exercisable and expire on June 22, 2035.
• Following this reported transaction, Mr. Christensen beneficially owns 16,000 derivative securities (stock options) and 16,000 underlying shares of common stock.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns the director's interests with shareholders, which is generally viewed as a positive for corporate governance and long-term value creation. It does not indicate any significant operational or financial changes.

Positives

• The grant of stock options to Director James Christensen aligns his financial interests with those of shareholders, incentivizing long-term value creation.
• The vesting schedule, which is tied to continued service on the board, promotes stability in leadership and commitment from the director.

Negatives

• No inherent negatives are disclosed in this Form 4 filing, as it primarily serves as a disclosure of an insider transaction.

Risks

• The value of the stock options is directly dependent on the future performance of Boundless Bio, Inc.'s stock price. If the stock price does not exceed the exercise price of $1.03, the options may not be profitable or may expire worthless.
• The vesting of the options is subject to the reporting person's continuing service on the issuer's board of directors, meaning the options could be forfeited if service ceases prematurely.

Future Outlook

The stock options granted to Director James Christensen are scheduled to vest in substantially equal monthly installments over the 12 months following June 23, 2025. There is a provision for accelerated vesting if the next annual meeting occurs prior to June 23, 2026, provided his service on the board continues.

Industry Context

The granting of stock options to directors is a standard and widespread practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors. This compensation method is commonly used to attract, retain, and incentivize key personnel by aligning their financial interests with the company's long-term performance and shareholder value creation.

Comparison to Industry Standards

• The practice of granting stock options to directors is consistent with industry standards for executive and board compensation.
• While the specific number of options (16,000) and exercise price ($1.03) are unique to this grant, the general structure of performance-based equity compensation with a vesting schedule tied to continued service is typical for director remuneration in the biotech sector.
• Without specific comparable companies' director compensation packages, a detailed quantitative comparison of the grant size relative to industry benchmarks is not feasible from this document alone.

Related Party Transactions

• The stock option grant to James Christensen, a director of Boundless Bio, Inc., constitutes a related party transaction as it involves compensation provided to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, potentially leading to better long-term performance and improved corporate governance.
• Employees: No direct impact on general employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• Continued service of James Christensen on the Boundless Bio, Inc. board of directors to ensure vesting of the options.
• Monthly vesting of the 16,000 stock options over the next 12 months, commencing June 23, 2025.
• Potential exercise of options by James Christensen upon vesting and if the stock price is favorable relative to the exercise price.

Key Dates

Keywords

Boundless Bio Inc., BOLD, SEC Form 4, Insider Transaction, Stock Option Grant, Director Compensation, Equity Incentive, James Christensen, Corporate Governance